A Single Arm, Open-label Multicenter Phase II Trial of Everolimus in Patients With Relapsed/Refractory Germ Cell Cancer.
Phase of Trial: Phase II
Latest Information Update: 25 May 2015
At a glance
- Drugs Everolimus (Primary)
- Indications Testicular cancer
- Focus Therapeutic Use
- Acronyms RADIT
- 24 Feb 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 03 Jun 2014 Interim analysis results in 13 patients presented at the 50th Annual Meeting of the American Society of Clinical Oncology.
- 21 Nov 2012 New source identified and integrated (German Clinical Trials Register: DRKS00004049).